Literature DB >> 24809815

Jehovah's Witnesses and cardiac surgery: a single institution's experience.

Sharon McCartney1, Nicole Guinn, Russell Roberson, Bob Broomer, William White, Steven Hill.   

Abstract

BACKGROUND: Based on biblical doctrines, patients of the Jehovah's Witness faith refuse allogeneic blood transfusion. Cardiac surgery carries a high risk of blood transfusion, but has been performed in Jehovah's Witnesses for many years. The literature contains information on the outcomes of this cohort, but does not detail the perioperative care of these patients. This article describes a single institution's experience in perioperative care of Jehovah's Witnesses undergoing cardiac surgery. STUDY DESIGN AND METHODS: A chart review of adult Jehovah's Witness patients undergoing cardiac surgery at Duke University between January 2005 and June 2012 was completed. Institutional protocols regarding preoperative erythropoietin (EPO) therapy and intraoperative isovolemic hemodilution are detailed. Patient demographics and use of various blood conservation techniques are described. Hemoglobin (Hb) at various points throughout the perioperative management, hospital length of stay, and mortality are reviewed as indicators of outcome.
RESULTS: Forty-five Jehovah's Witness patients underwent cardiac surgery at Duke University Medical Center. Preoperative EPO increased the mean Hb by 1.2 g/dL before surgery. Intraoperative normovolemic hemodilution was used in 37 patients with intraoperative mean nadir Hb of 10.3 g/dL. Antifibrinolytics and desmopressin were commonly used as coagulation adjuncts. Mean cardiopulmonary bypass time was 137 minutes, with mean nadir temperature of 30.5°C. The mean length of hospital stay was 6.2 days, with mean intensive care unit stay of 1.7 days. This cohort had zero 90-day mortality in the perioperative period.
CONCLUSIONS: This case series demonstrates that bloodless cardiac surgery can be performed in select patients refusing allogeneic blood transfusion.
© 2014 AABB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24809815     DOI: 10.1111/trf.12696

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Implementing a protocol to optimize blood use in a cardiac surgery service: results of a pre-post analysis and the impact of high-volume blood users.

Authors:  Juan B Grau; Jacqueline H Fortier; Cyrus Kuschner; Giovanni Ferrari; Mariano E Brizzio; Alex Zapolanski; Richard E Shaw
Journal:  Transfusion       Date:  2017-07-16       Impact factor: 3.157

2.  Religious Identity and Health Inequalities in Canada.

Authors:  Maryam Dilmaghani
Journal:  J Immigr Minor Health       Date:  2018-10

3.  The Novel Use of a Low Prime Modified Ultrafiltration Apparatus in a 13-kg Jehovah's Witness Patient: A Case Report.

Authors:  Bharat Datt; Hamish M Munro; William M DeCampli
Journal:  J Extra Corpor Technol       Date:  2018-09

4.  Harms associated with single unit perioperative transfusion: retrospective population based analysis.

Authors:  Elizabeth L Whitlock; Helen Kim; Andrew D Auerbach
Journal:  BMJ       Date:  2015-06-12

5.  Are there morally relevant differences between hymen restoration and bloodless treatment for Jehovah's Witnesses?

Authors:  Niklas Juth; Niels Lynøe
Journal:  BMC Med Ethics       Date:  2014-12-23       Impact factor: 2.652

6.  Cardiac Surgery in Jehovah's Witness Patients: Experience of a Brazilian Tertiary Hospital.

Authors:  Felipe Homem Valle; Fernando Pivatto Júnior; Bruna Sessim Gomes; Tanara Martins de Freitas; Vanessa Giaretta; Miguel Gus
Journal:  Braz J Cardiovasc Surg       Date:  2017 Sep-Oct

7.  Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx.

Authors:  Alejandro Murillo-Berlioz; Nicole R Guinn; Jerrold H Levy; Carmelo A Milano
Journal:  JTCVS Tech       Date:  2020-08-04

Review 8.  Outcomes of cardiac surgery in Jehovah's Witness patients: A review.

Authors:  Aimee-Louise Chambault; Louise J Brown; Sophie Mellor; Amer Harky
Journal:  Perfusion       Date:  2020-12-16       Impact factor: 1.972

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.